Jeito Capital appoints Samit Hirawat, M.D., as Strategic Medical Advisor to strengthen Jeito’s leadership in driving innovations for patient benefit

• Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities.
• His expertise will contribute to Jeito’s proven investment strategy and methodology, driving the portfolio to the highest standards and with the shared ambition of developing innovative therapies that deliver transformative patient benefit.

Paris, France, March 11th, 2026 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, is pleased to announce that it has appointed Samit Hirawat, M.D., as a Strategic Medical Advisor.
His extensive expertise in clinical development, leadership experience, and proven record in patient-driven therapeutic innovation at leading global pharmaceutical companies will further enlarge the strategic capabilities of Jeito’s team, which integrates expertise across the entire drug value chain. Samit Hirawat, M.D., will contribute to the investment strategy and provide exceptional guidance to all portfolio companies.

Most recently, Samit Hirawat, M.D., served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas and modalities to registration trials and approvals. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic responsibility, leading to his position as Executive Vice President and Head of Oncology Development.

Samit Hirawat, M.D., earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College. He completed his Internal Medicine residency and Medical Oncology fellowship at North Shore University Hospital. He has published more than 150 peer-reviewed manuscripts and abstracts across therapeutic areas.

The appointment of Samit Hirawat M.D. continues the recent expansion of Jeito Capital, which has firmly established itself as one of Europe’s leading independent biopharma investors. Last year, the firm announced the promotions of Ksenija Pavletic to General Partner and Mehdi Ainouche to Partner, as well as the appointment of Pascal Touchon, MBA, Doctor of Veterinary Medicine, formerly in senior positions in the U.S. and at global companies (including Novartis, Servier and GSK), as Operating Partner, further strengthening its leadership team and its commitment to a patient benefit-driven approach.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “We are delighted to welcome Samit, with whom we share a commitment to innovation in serving patients with high unmet needs. His extensive expertise and proven experience at leading global pharmaceutical companies add a valuable dimension to our team’s collective capabilities and contribute to developing our portfolio to the highest standards. We look forward to collaborating as we continue to grow and accelerate the development of our portfolio companies.”

Samit Hirawat, MD, Strategic Medical Advisor at Jeito Capital, added: “I am very happy to take a new step as Strategic Medical Advisor at Jeito Capital. I am thrilled to collaborate with such a talented team and contribute to their mission. Dr Rafaèle Tordjman and her team have built a reputation as a world-class platform for investing in some of the most innovative biopharmaceutical companies, while fostering a collaborative approach that allows them to thrive. I am very much looking forward to bringing my expertise to support Jeito as it expands its portfolio.”

About Jeito Capital

Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit www.jeito.life or follow us on LinkedIn.

For further information please contact:

H/Advisors Maitland
Finlay Donaldson
finlay.donaldson@h-advisors.global
Tel: +44 (0) 7341 788 066